A practical reference on PPARδ agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-25 and is reviewed periodically as new material appears.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
| Property | Value | Notes |
|---|---|---|
| Molecular target | PPAR delta (NR1C2) | Ligand-activated nuclear receptor. |
| Primary tissues studied | Skeletal muscle, liver, adipose | Effects on fatty acid oxidation and energy use. |
| Typical detection matrix | Urine | Used in anti-doping analysis. |
| Common analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Sport regulatory class | Prohibited at all times | Listed as a metabolic modulator by WADA. |
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Sontra Medical, Inc. (acquired by Echo Therapeutics) fqubed, Inc. (acquired by Nuvo Research) Stratagent LifeSciences (acquired by Corium International) Seventh Sense Biosystems (now Your Bio Health, acquired by Hims and Hers) Dx Biosciences Entrega Liquideon, LLC CAGE Bio Inc. Fount Biosciences inTumo Therapeutics i2o Therapeutics Trillion Bio
=== Protein degradation === Arginine phosphorylation by McsB kinase marks proteins for degradation by a Clp protease. The arginine phosphorylation system, which is widely distributed across Gram-positive bacteria, appears to be functionally analogous to the eukaryotic ubiquitin–proteasome system.
== Molecular Structure of EAATs == Like all glutamate transporters, EAATs are trimers, with each protomer consisting of two domains : the central scaffold domain (Figure 1A, wheat) and the peripheral transport domain (Figure 1A, blue). The transport conformational path is as follows. First, the outward facing conformation occurs (OF, open) which allows the glutamate to bind. Then the HP2 region closes after uptake (OF, closed) and the elevator like movement carries the substrate to the intracellular side of the membrane. It worth nothing that this elevator motion consists of several yet to be categorized/identified conformational changes. After the elevator motion brings the substrate to the IC side of the membrane, EAAT adopts the inward facing (IF, closed) state in which the transport domain is lowered, but the HP2 gate is still closed with the glutamate still bound to the transporter. Lastly, the HP2 gate opens and the glutamate diffuses into the cytoplasm of the cell.
where V100 is the volume occupied by a given sample of gas at 100 °C; V0 is the volume occupied by the same sample of gas at 0 °C; and k is a constant which is the same for all gases at constant pressure. This equation does not contain the temperature and so is not what became known as Charles's Law. Gay-Lussac's value for k (1⁄2.6666), was identical to Dalton's earlier value for vapours and remarkably close to the present-day value of 1⁄2.7315. Gay-Lussac gave credit for this equation to unpublished statements by his fellow Republican citizen J. Charles in 1787. In the absence of a firm record, the gas law relating volume to temperature cannot be attributed to Charles. Dalton's measurements had much more scope regarding temperature than Gay-Lussac, not only measuring the volume at the fixed points of water but also at two intermediate points. Unaware of the inaccuracies of mercury thermometers at the time, which were divided into equal portions between the fixed points, Dalton, after concluding in Essay II that in the case of vapours, “any elastic fluid expands nearly in a uniform manner into 1370 or 1380 parts by 180 degrees (Fahrenheit) of heat”, was unable to confirm it for gases.
Sources: en.wikipedia.org
In February 1941, Banting died of wounds and exposure following the crash of a Lockheed L-14 Super Electra/Hudson in which he was a passenger, in Musgrave Harbour, Newfoundland. After departing from Gander, Newfoundland, both of the plane's engines failed. The navigator and co-pilot died instantly, but Banting and the pilot, Captain Joseph Mackey, survived the initial impact. According to Mackey, the sole survivor, Banting died from his injuries the next day. Banting was en route to England to conduct operational tests on the Franks flying suit developed by his colleague Wilbur Franks. Banting and his wife are buried at Mount Pleasant Cemetery in Toronto.
=== Molecular structure of Cu(II)-histidine and ATCUN Motif === Sarkar solved the structure of the copper(II)-histidine molecule used for the treatment of Menkes disease. He discovered the ATCUN (Amino terminal Cu(II), Ni(II) binding) motif of proteins and peptides.
== Killing == At the time of her death, Nickell was aged 23 and lived near Wimbledon Common with partner André Hanscombe and their two-year-old son, Alexander Louis. On the morning of 15 July 1992, she and Alexander were walking their dog on Wimbledon Common. While passing through a secluded area, Nickell was repeatedly stabbed and sexually assaulted. Alexander was physically unharmed, and was found by a passer-by clinging to Nickell's body, repeating the words "Wake up, Mummy", having placed a piece of paper on her forehead as a makeshift bandage.
The domesticated saffron crocus, Crocus sativus, is an autumn-flowering perennial plant unknown in the wild. It possibly descends from the eastern Mediterranean autumn-flowering Crocus cartwrightianus which is also known as "wild saffron" and is native to mainland Greece, Euboea, Crete, Skyros and some islands of the Cyclades. The similar species C. thomasii and C. pallasii were considered as other possible ancestors. As a genetically monomorphic clone incapable of seed production, it was slowly propagated by humans throughout much of Eurasia. Various origins have been suggested for saffron, including Iran, Mesopotamia, Kashmir and Greece.
== Definition == The shutdown margin for nuclear reactors (that is, when the reactor is considered to be safely in a shutdown state) is usually defined either in terms of reactivity or dollars. For reactivity, this is calculated in units of delta-k/k, where k is equal to the criticality of the reactor (essentially, how fast and controlled the nuclear fission reaction is). It is sometimes also measured in dollars, where one dollar is equal to a reactor in prompt criticality, this can then be used to calculate the change in reactivity required to shut down or start up the reactor. The shutdown margin for each reactor can either refer to the margin by which a reactor is subcritical with all its control rods inserted, or as the margin by which the reactor would be shut down in the event of a SCRAM. This margin has to be considered carefully for each reactor and reactor design, to ensure that it remains within the technical specifications and limitations of the reactor.
Sources: en.wikipedia.org
== Function == Thyrotropin-stimulating hormone (TSH) is a noncovalently linked glycoprotein heterodimer and is part of a family of pituitary hormones containing a common alpha subunit (TSHA) and a unique beta subunit (this protein) that confers specificity.
== Bibliography == Olofsson, Clark (1986). Rättvisans lotteri [The Lottery of Justice] (in Swedish). Stockholm: Prisma. ISBN 91-518-2030-7. SELIBR 7407420. Olofsson, Clark (2015). Vafan var det som hände? [What the Hell Happened?] (in Swedish). Stockholm: Upp med händerna i samarbete med Ordupplaget. ISBN 9789185785957. SELIBR 17921760.
=== In-situ monitoring techniques === In-situ monitoring techniques observe the ion milling process in real-time. One type of in-situ monitoring is optical emission spectroscopy (OES). OES monitors the emission of light during ion milling and gives information about the plasma.
The oxygen transmission rate of a gas through packaging is defined as the amount of oxygen permeating per unit of permeable area and per unit of time in a packaging system considering standardized test conditions (23 °C and 1 atm. partial pressure difference). It is an effective tool to estimate the barrier properties of a certain material. The determination of the OTR is usually carried out by means of a steady-state and isostatic method, reported by the ASTM D 3985 or ASTM F 1307, containing respectively standardized protocols for the measurements of the OTR of several kinds of packaging. The typical instrumentation consists in a permeation cell composed by two distinct chambers, separated by the tested material; one of the chambers is then filled with a carrier gas (e.g., nitrogen), while the other one with oxygen, hence creating the necessary driving force to let the oxygen permeate across the barrier's material.
Sources: en.wikipedia.org
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.
Early-stage trials examined lipid and glucose markers, but the development program was discontinued. Published human results are limited and do not support approved use for any indication. Claims of performance or health benefits remain unproven.
Yes. Laboratories use LC-MS/MS to detect GW501516 and its metabolites in urine. Detection depends on timing and sensitivity, but the substance is banned at all times.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.